Effects of Aromatase Inhibition in Elderly Men with Low or Borderline-Low Serum Testosterone Levels
The DOI matches its Crossref record; 63 of the 68 references it cites were found in a registry or an index.
Abstract
As men age, serum testosterone levels decrease, a factor that may contribute to some aspects of age-related physiological deterioration. Although androgen replacement has been shown to have beneficial effects in frankly hypogonadal men, its use in elderly men with borderline hypogonadism is controversial. Furthermore, current testosterone replacement methods have important limitations. We investigated the ability of the orally administered aromatase inhibitor, anastrozole, to increase endogenous testosterone production in 37 elderly men (aged 62–74 yr) with screening serum testosterone levels less than 350 ng/dl. Subjects were randomized in a double-blind fashion to the following 12-wk oral regimens: group 1: anastrozole 1 mg daily (n = 12); group 2: anastrozole 1 mg twice weekly (n = 11); and group 3: placebo daily (n = 14). Hormone levels, quality of life (MOS Short-Form Health Survey), sexual function (International Index of Erectile Function), benign prostate hyperplasia severity (American Urological Association Symptom Index Score), prostate-specific antigen, and measures of safety were compared among groups. Mean ± sd bioavailable testosterone increased from 99 ± 31 to 207 ± 65 ng/dl in group 1 and from 115 ± 37 to 178 ± 55 ng/dl in group 2 (P < 0.001 vs. placebo for both groups and P = 0.054 group 1 vs. group 2). Total testosterone levels increased from 343 ± 61 to 572 ± 139 ng/dl in group 1 and from 397 ± 106 to 520 ± 91 ng/dl in group 2 (P < 0.001 vs. placebo for both groups and P = 0.012 group 1 vs. group 2). Serum estradiol levels decreased from 26 ± 8 to 17 ± 6 pg/ml in group 1 and from 27 ± 8 to 17 ± 5 pg/ml in group 2 (P < 0.001 vs. placebo for both groups and P = NS group 1 vs. group 2). Serum LH levels increased from 5.1 ± 4.8 to 7.9 ± 6.5 U/liter and from 4.1 ± 1.6 to 7.2 ± 2.8 U/liter in groups 1 and 2, respectively (P = 0.007 group 1 vs. placebo, P = 0.003 group 2 vs. placebo, and P = NS group 1 vs. group 2). Scores for hematocrit, MOS Short-Form Health Survey, International Index of Erectile Function, and American Urological Association Symptom Index Score did not change. Serum prostate-specific antigen levels increased in group 2 only (1.7 ± 1.0 to 2.2 ± 1.5 ng/ml, P = 0.031, compared with placebo). These data demonstrate that aromatase inhibition increases serum bioavailable and total testosterone levels to the youthful normal range in older men with mild hypogonadism. Serum estradiol levels decrease modestly but remain within the normal male range. The physiological consequences of these changes remain to be determined.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These compounds have been shown to raise testosterone levels in hypogonadal men and are also orally administered (64-66).”
From Non-testosterone management of male hypogonadism: an examination of the existing literature (2020) · cites this paper as [65]
In the citing paper
“Aromatase inhibitors effectively delay epiphysial maturation in boys and improve testosterone levels in adult men”
From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [29]
In the citing paper
“In men third-generation aromatase inhibitors will decrease the mean plasma estradiol/testosterone ratio by 77% [28,29].”
From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [29]
In the citing paper
“Lowering estradiol levels, by administering an aromatase inhibitor, is associated with an increase in levels of LH, follicle-stimulating hormone (FSH) and testosterone [28,29].”
From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [29]
In the citing paper
“Although aromatase inhibition by anastrozole and letrozole is reported to be close to 100%, administration of these inhibitors to men will not suppress plasma estradiol levels completely.”
From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [29]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Rosen, R. C., Riley, A., Wagner, G., Osterloh, I. H., Kirkpatrick, J., & Mishra, A. (1997) · Urology · doi:10.1016/s0090-4295(97)00238-0 · Cited by 5,849
Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men
Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J., & Blackman, M. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7219 · Cited by 2,760
Feldman, H. A., Longcope, C., Derby, C. A., Johannes, C. B., Araujo, A. B., Coviello, A. D., Bremner, W. J., & McKinlay, J. B. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8201 · Cited by 1,861
Self-citationGRAY, A., FELDMAN, H. A., MCKINLAY, J. B., & LONGCOPE, C. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-5-1016 · Cited by 1,118
Self-citationTestosterone Replacement in Older Hypogonadal Men: A 12-Month Randomized Controlled Trial
Sih, R. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.6.1661 · Cited by 922
Morley, J. E., Kaiser, F. E., Perry, H. M., Patrick, P., Morley, P. M. K., Stauber, P. M., Vellas, B., Baumgartner, R. N., & Garry, P. J. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90057-3 · Cited by 830
Effects of testosterone supplementation in the aging male
Tenover, J. S. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.4.1092 · Cited by 768
Falahati-Nini, A., Riggs, B. L., Atkinson, E. J., O’Fallon, W. M., Eastell, R., & Khosla, S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10942 · Cited by 757
Research works printed but not linked: 1
- Med Lett Drugs Ther, 42, 49
Cited by
Items 101–149 of 149
Aboelnaga, M. M., & Elshahawy, H. A. (2016) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20162298 · Cited by 9
Dutta, D., Mohindra, R., Kumar, M., & Sharma, M. (2022) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_3_22 · Cited by 6
Diagnosis and treatment of hypogonadism in men seeking to preserve fertility – what are the options?
Lockie, A. W. C., Grice, P., Mathur, R., Pearce, I., & Modgil, V. (2024) · International Journal of Impotence Research · doi:10.1038/s41443-024-00897-4 · Cited by 4
The Role of Testosterone Therapy in Cardiovascular Mortality: Culprit or Innocent Bystander?
Tanna, M. S., Schwartzbard, A. Z., Berger, J. S., Alukal, J. P., & WEINTRAUB, H. S. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0490-0 · Cited by 5
Sex Hormones and Immunosenescence
Gómez, C. R., Nomellini, V., & Kovacs, E. J. (2009) · Springer eBooks · doi:10.1007/978-1-4020-9063-9_42 · Cited by 5
High Prevalence of Y Chromosome Partial Microdeletions in Overweight Men.
Biabangard-Zak, A., Golalipour, M., & Hadadchi, G. (2015) · PubMed Central · Cited by 5
Diabetes mellitus is associated with subnormal levels of free testosterone in men
Cohen, P. G. (2006) · British Journal of Urology · doi:10.1111/j.1464-410x.2006.06111_2.x · Cited by 5
Wood, C. E., Stavisky, R. C., Nowak, J., & Kaplan, J. R. (2011) · Toxicologic Pathology · doi:10.1177/0192623311425509 · Cited by 3
Tratamiento farmacológico en la hiperplasia prostática benigna
Guerra, Y. P., Cuevas, V. M., Yera, Á. O., & Ferrei, R. M. (2011) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 3
Nutritional Supplements for Strength Power Athletes
Wilborn, C. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-231-1_10 · Cited by 4
Androgen deficiency in aging men
T'Sjoen, G. G., & Kaufman, J. (2006) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000224805.31695.6a · Cited by 3
Li, L., Wu, G., Xu, X., Yang, J., Yi, L., Yang, Z., Mo, Z., Li, X., Shan, Y., Yu, Z., et al. (2024) · eLife · doi:10.7554/elife.100346.4 · Cited by 3
Reznikov, O. H., Sachynska, O. V., Polyakova, L. I., Faliush, O. A., & Yanishevskyi, O. V. (2018) · Pathologia · doi:10.14739/2310-1237.2018.3.151647 · Cited by 2
Nutritional Supplements for Strength and Power Athletes
Wilborn, C. (2015) · Springer eBooks · doi:10.1007/978-3-319-18230-8_10 · Cited by 2
Khera, M., Hotaling, J., & Miner, M. M. (2025) · Sexual Medicine Reviews · doi:10.1093/sxmrev/qeaf011 · Cited by 3
Other Hormonal Therapies and Men's Health
Hawksworth, D. J., & Burnett, A. L. “. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816665-9.00013-5 · Cited by 4
Testosterone supplementation therapy as a treatment of hypogonadism
Schmidtová, E., Kelemenová, S., & Ostatníková, D. (2009) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/bf03657269 · Cited by 2
An Overview of Doping in Sports
Sanchis‐Gomar, F., Martinez-Bello, V. E., Pareja-Galeano, H., Brioche, T., & Gómez‐Cabrera, M. C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813922-6.00016-3 · Cited by 3
Letter re: Endogenous Sex Hormones and Metabolic Syndrome in Aging Men
Cohen, P. G. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0903 · Cited by 2
A Clinical Paradigm for the Combined Management of Androgen Insufficiency and Erectile Dysfunction
Goldstein, I. (2007) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2007.02.002 · Cited by 2
An Overview of Doping in Sports
Sanchis‐Gomar, F., Martinez-Bello, V. E., Pareja-Galeano, H., Brioche, T., & Gómez‐Cabrera, M. C. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-396454-0.00018-7 · Cited by 2
Adjunct Management of Male Hypogonadism
Bach, P. V., Najari, B. B., & Kashanian, J. A. (2016) · Current Sexual Health Reports · doi:10.1007/s11930-016-0089-7 · Cited by 3
Effects of Testosterone Replacement on Lower Urinary Tract Functions in Elderly Male Rats
Morizane, S. (2005) · Institutional Repositories DataBase (IRDB) · Cited by 1
Problema: invecchiamento maschile
Kaufman, J., Comhaire, F. H., Mahmoud, A., & MEULEMAN, E. J. H. (2010) · Springer eBooks · doi:10.1007/978-88-470-1487-9_17
Pitts, W. R. (2008) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.07417_1.x
Possible additional therapeutic uses of aromatase inhibitors
Furr, B. J. A. (2008) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8693-1_9
Re: Hypogonadism and Metabolic Syndrome: Implications for Testosterone Therapy
Cohen, P. G. (2006) · The Journal of Urology · doi:10.1016/s0022-5347(06)00327-2
Neuroendocrine Regulation of Testicular Function
Kaufman, J. (2006) · Springer eBooks · doi:10.1007/3-540-33713-x_53
Sperm Count Improvement in a Cancer-Surviving Patient
Pereira, M. C., Vieira, M. M. D. S., & Simões‐Pereira, J. (2015) · Case Reports in Oncology · doi:10.1159/000438668
Androgens and the Skeleton – Humans
Leder, B. Z. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374602-3.00026-2
Self-citationAlternate Therapies for Testosterone Replacement
Şerefoğlu, E. C., Gökçe, A., Hellstrom, W. J. G., & Guay, A. T. (2012) · Humana Press eBooks · doi:10.1007/978-1-62703-179-0_11
Effect of In Ovo Injection of Anastrozole on Sex Ratio and Quality of Broiler Chicks
Kavianpoor, M., Pirsaraei, Z. A., Dirandeh, E., & Shohreh, B. (2019) · Research on Animal Production · doi:10.29252/rap.10.24.85
Akram, N. M., Gopal, N. M., Balakrishna, A., & Reddy, N. B. (2020) · AIP conference proceedings · doi:10.1063/5.0018206
Rastrelli, G., Maggi, M., & Corona, G. (2022) · doi:10.1093/med/9780198870197.003.0387
Possible additional therapeutic uses of aromatase inhibitors
Furr, B. J. A. (2006) · Birkhäuser Basel eBooks · doi:10.1007/3-7643-7418-7_9
Maintenance of Fertility in the Male Patient with Hypogonadism
Lo, E. M., & Khera, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-99918-6_6
Male Hypogonadism and Fertility
Khalafalla, K. M., de Souza, R. P., Ohlander, S. J., & NIEDERBERGER, C. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-31501-5_11
Bagavathithasan, P., Dash, S. S., Venkatachalam, L., Shetye, V. A., Pankaj, S., Bhate, J., & Rao, G. K. S. (2024) · Annals of Medical Science and Research · doi:10.4103/amsr.amsr_30_23
Li, L., Wu, G., Xu, X., Yang, J., Yi, L., Yang, Z., Mo, Z., Li, X., Shan, Y., Yu, Z., et al. (2024) · eLife · doi:10.7554/elife.100346.1 · Cited by 1
Li, L., Wu, G., Xu, X., Yang, J., Yi, L., Yang, Z., Mo, Z., Li, X., Shan, Y., Yu, Z., et al. (2024) · eLife · doi:10.7554/elife.100346
Männlicher Hypogonadismus und Fruchtbarkeit
Khalafalla, K. M., de Souza, R. P., Ohlander, S. J., & NIEDERBERGER, C. S. (2024) · Springer eBooks · doi:10.1007/978-3-031-65245-5_11
Li, L., Wu, G., Xu, X., Yang, J., Yi, L., Yang, Z., Mo, Z., Li, X., Shan, Y., Yu, Z., et al. (2024) · eLife · doi:10.7554/elife.100346.2
Smit, D. L., Verdegaal, T. J., & Bond, P. (2025) · Performance Enhancement & Health · doi:10.1016/j.peh.2025.100377
Li, L., Wu, G., Xu, X., Yang, J., Yi, L., Yang, Z., Mo, Z., Li, X., Shan, Y., Yu, Z., et al. (2025) · eLife · doi:10.7554/elife.100346.3 · Cited by 1
Problème: vieillissement masculin
Kaufman, J., Comhaire, F. H., Mahmoud, A., & MEULEMAN, E. J. H. (2008) · Springer eBooks · doi:10.1007/978-2-287-72080-2_17
Bandura, A., Ďurina, P., Cambal, E., & Kečkéš, Š. (2026) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2026.107121
Understanding Aromatase: A Mechanistic Basis for Drug Interactions and New Inhibitors
Lu, W. J. (2012) · IUScholarWorks (Indiana University) · doi:10.7912/c2/294
The Voice of a Special Patient
Aebi, S. P. (2009) · Cancer treatment and research · doi:10.1007/978-0-387-75115-3_28
Metadata
- Authors
- Leder, B. Z., Rohrer, J. L., Rubin, S. D., Gallo, J., & Longcope, C.
- Affiliations
- Massachusetts General Hospital (US)
- AstraZeneca (United States) (US)
- AstraZeneca Pharmaceuticals (S.D.R., J.G.), Wilmington, Delaware 19850
- University of Massachusetts Chan Medical School (US)
- ORCID
- Leder, Benjamin Z.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2004-03-01
- Volume
- 89
- Issue
- 3
- Pages
- 1174-1180
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2117332496
- Semantic Scholar
- aedcb017eb7fc20eca8962b9ec633cc90042cd64
- Cited by
- 149
- References
- 68
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 6 · 2023: 3 · 2022: 6 · 2021: 5 · 2020: 7 · 2019: 8 · 2018: 5 · 2017: 3 · 2016: 10 · 2015: 8 · 2014: 7 · 2013: 6 · 2012: 5
- FWCI
- 7.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Center for Research Resources (K23 RR 16310, K23RR016310)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Keywords
- anastrozole, aromatase inhibitors, older men, androgen deficiency, testosterone replacement therapy, estradiol suppression, luteinizing hormone, sexual function, erectile function, benign prostatic hyperplasia, quality of life, adverse effects, drug safety, age-related testosterone decline, prostate-specific antigen, LH/FSH ratio
- MeSH terms
- Anastrozole, Aged, Aging, Enzyme Inhibitors, Estrogens, Humans, Hypogonadism, Male, Middle Aged, Nitriles, Quality of Life, Testosterone, Triazoles, Treatment Outcome, Aromatase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.